- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Inspire agrees to sell InSite anti-infective
Alameda, CA-Inspire Pharmaceuticals plans to commercialize InSite Vision Inc.'s topical anti-infective for treating bacterial conjunctivitis (AzaSite).
Alameda, CA-Inspire Pharmaceuticals plans to commercialize InSite Vision Inc.'s topical anti-infective for treating bacterial conjunctivitis (AzaSite).
The product combines a topical 1% azithromycin formulation with InSite's patented ophthalmic drug-delivery system (DuraSite), designed to increase ocular retention of the drug.
Under the agreement, InSite will grant Inspire exclusive rights to market the anti-infective in the United States and Canada. Inspire will make an initial $13 million payment to InSite, with an additional $19 million pending FDA grants regulatory approval. Inspire also will pay a 20% royalty on net sales for the first 2 years and 25% thereafter.
